Where ORIC Pharmaceuticals Stands With Analysts
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 4 Wall Street analysts have published opinions on ORIC Pharmaceuticals (NASDAQ:ORIC), with 2 giving a bullish and 2 a somewhat bullish rating. The average 12-month price target for ORIC is $14.75, with a high of $16.00 and a low of $14.00. This target has increased by 1.72% from the previous target of $14.50. Analysts typically review stocks quarterly or after major company updates, using financial predictions and company performance to guide their ratings.
December 13, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ORIC Pharmaceuticals has received positive ratings from analysts, with an updated average price target of $14.75, suggesting a bullish sentiment.
The unanimous bullish and somewhat bullish ratings from analysts, combined with an increased price target, indicate a positive outlook for ORIC Pharmaceuticals. This consensus could lead to increased investor confidence and a potential rise in ORIC's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100